Today, Foundation Medicine and our collaborators presented data at the American Society of Clinical Oncology (ASCO) annual meeting demonstrating that tumor mutational burden (TMB) measured by FoundationOne comprehensive genomic profiling (CGP) is a potentially more sensitive method for identifying responders to …

Cancer immunotherapies are revolutionizing the world of oncology. This exciting new class of medicines retrains the body’s own immune system to fight cancer. Unlike cytotoxic chemotherapy, the immune system is “smart” and can adapt and evolve with the cancer over time – potentially resulting in unprecedented long-term …

The oncology community is gearing up for the largest gathering of the year, the American Society of Clinical Oncology Annual Meeting (ASCO), which will take place June 3-7 in Chicago. The meeting is a critically important annual gathering of thousands of experts where the latest scientific breakthroughs and exciting …

At the White House Precision Medicine Initiative Summit in February, we announced our intention to release genomic profiles of pediatric cancers currently maintained as part of our information knowledgebase, FoundationCORE™. Today, we’re proud to fulfill this commitment and provide the cancer research community with a …

New data published today in The Oncologist by Siraj M. Ali, M.D., Ph.D., our very own associate director, clinical development and medical affairs, along with our collaborators, revealed clinically relevant genomic alterations in penile squamous cell carcinoma (PSCC), a rare cancer for which the oncogenic drivers have …

Here at Foundation Medicine, we’re always excited when we can report important new data that could help improve clinical outcomes for patients. This week, at the American Society of Hematology (ASH) Annual Medical Meeting, we and our collaborators presented exciting new data supporting the use of FoundationOne Heme in …

A new clinical case study published in a research letter in JAMA Oncology shows a beneficial clinical outcome for a patient with a rare tumor type as a result of comprehensive genomic profiling with FoundationOne. The patient, a woman in her 30’s, was diagnosed with an advanced acinic cell tumor of the right parotoid …

Pediatric cancer is devastating for patients and families, particularly when the diagnosis and appropriate course of therapy are difficult to determine. This was the case for a one-month-old with a recurrent sarcoma, eventually diagnosed as ETV6-NTRK3 negative congenital infantile fibrosarcoma (CIFS), whose disease …

Discordance Between Medicare Administrative Contractors’ Policies Threatens Uniform Access to Quality Care for Medicare Recipients with Lung Cancer National Government Services, Inc. (NGS), the Medicare Administrative Contractor, or MAC, that covers certain geographies of the United States, including Massachusetts, …

Recent estimates cite the risk-adjusted cost of bringing a new drug to approval to be north of $2.5 billion. This is a staggering amount, particularly when less than 10 percent of newly innovated therapeutics survive the clinical development process. Indeed, drug development is fraught with high costs and low …